Spartalizumab combo with Tafinlar + Mekinist fails in Phase III advanced melanoma study

Source: thepharmaletter, August 2020

The Phase III COMBI-i study evaluating the immunotherapy spartalizumab (PDR001), in combination with…

To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.

Or, if you’re only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO and CMO, and regulation), then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.

READ THE ORIGINAL FULL ARTICLE